Arvinas Inc. is a clinical-stage biopharmaceutical company focused on developing protein degradation therapies, particularly for cancer. Their lead candidate, Vepdegestrant, targets metastatic ER+/HER2- breast cancer, a significant market with unmet needs.
© 2025 Future Classic Equity Research
Substack is the home for great culture